• Ardelyx, Inc. has reported past full-year 2025 results, with revenue of US$407.32 million versus US$333.62 million a year earlier, while net loss widened to US$61.60 million and basic loss per share from continuing operations rose to US$0.26.
• Alongside these results, Ardelyx issued ambitious 2026 product revenue guidance for IBSRELA and XPHOZAH, highlighting management’s confidence in demand for its two commercial therapies.
• We’ll now examine how Ardelyx’s upbeat 2026 revenue outlook, especially for IBSRELA, may influence the company’s existing investment narrative.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Ardelyx Investment Narrative Recap

To own Ardelyx, you need to be comfortable with a focused biotech story built around tenapanor, believing IBSRELA and XPHOZAH can eventually support a profitable business despite current losses. The new 2026 revenue guidance reinforces IBSRELA as the key near term catalyst, while the widening net loss and ongoing reimbursement uncertainty around XPHOZAH remain central risks that this latest update does not fully resolve.

The most relevant recent announcement here is Ardelyx’s 2026 product revenue outlook, calling for US$410 to US$430 million from IBSRELA and US$110 to US$120 million from XPHOZAH. This guidance amplifies the importance of execution on IBSRELA growth at the same time as Ardelyx is investing in the Phase 3 ACCEL trial in chronic idiopathic constipation, which could become a future growth driver but also adds to near term expense pressure.

Yet, while guidance looks encouraging, investors should also be aware that reimbursement setbacks and concentrated product risk could still...

Ardelyx's narrative projects $704.6 million revenue and $178.8 million earnings by 2028.

Uncover how Ardelyx's forecasts yield a $13.50 fair value, a 103% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming roughly US$526 million in revenue and US$57.5 million in earnings by 2028, and their focus on reimbursement setbacks and dependence on IBSRELA and XPHOZAH shows how differently you might view this new guidance and what it could mean for future updates to those expectations.

Explore 9 other fair value estimates on Ardelyx - why the stock might be worth just $10.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ardelyx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ardelyx's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.